The gastrointestinal (GI) responses to ingested digestion resistant retrograded maltodextrins, having a structural similarity to type 3 resistant starch (RS) but a lower molecular weight, were studied after acute single bolus ingestion as well as during a medium-term period of daily ingestion. The overall study was split into two parts: part 1 aimed (1) to determine the GI responses of young adults following consumption of 0-60 g resistant maltodextrin; (2) to define the maximum non-effective dose (MNED) at which a considerable increase in symptoms did not occur. Part 2 aimed to determine whether a gradual increase in the daily dose of retrograded resistant maltodextrin (RRM) to a level finally exceeding by at least 10 g the individually determined MNED to acute ingestion in part 1 of the study, modified tolerance over time. Design: Study part 1 was executed as a randomized double-blind placebo-controlled crossover study and study part 2 as a longitudinal study. Subjects: Forty-one healthy adult volunteers aged 18-24 years were recruited from the student population of the University of Salford. All subjects enrolled and completed study part 1 and 39 subjects enrolled and completed study part 2. Interventions: In study part 1, individuals consumed, in random order 0, 20, 40, 60, 80, 100 or 120 g of a RRM containing starch product incorporated in pre-prepared foods on individual test days. Assuming a minimum content of 50% RRM in the starch product this delivered respectively 0, 10, 20, 30, 40, 50 or 60 g of RRM. All foods were prepared and coded by personnel not involved in carrying out the tests. Test days were separated by 7 day washout periods. In study part 2, consumption of RRM was increased from 3.6 g at day 1 in incremental doses up to each subject's MNED as determined in study 1, to be achieved at day 14. Subsequently, RRM intake was from day 15-21 in a way that the final intake at day 21 was at least 10 g above the individual MNED. In both parts of the study, subjects reported the prevalence and magnitude of GI symptoms. Results: No significant change was observed in either defecation frequency and faecal consistency or the number of subjects experiencing any GI symptoms, following consumption of foods containing 0-60 g RRM. The individual MNED at which an increase in symptoms did not occur was determined as 60 g RRM for 71% of the subjects who participated in study part 1. Regression analysis showed that consumption of gradually increasing doses of RRM in food products over 21 days was associated with a significant increase in the mean symptom score for flatulence (P ¼ 1.5 Â 10 À4 ), total bowel movement frequency (P ¼ 0.023) and bowel movement frequency to pass watery faeces (P ¼ 0.0157). Increasing the ingested dose of RRM by 10 g above the predetermined MNED, however, did not provoke significant increases in GI symptoms. In both studies, the majority of symptom responses were classified by the subjects as 'little more than usual'. Conclusions: Consumption of up to 60 g RRM is tolerated well by most individuals with no evidence of any significant dosedependent increase in the magnitude of symptoms or the occurrence of multiple GI symptoms. However, a mild laxative effect when consuming 460 g RRM is suggested. Although there was no change in GI responses following consumption of increasing doses of RRM over 21 days, generally a dose of 10 g RRM above the MNED level was tolerated well during medium term intake.
Introduction
During the last decade, there has been an intensified interest in the role of resistant starch (RS) being a well-fermentable digestion-resistant carbohydrate, having the potential to modify gut microflora and gut luminal contents in a potentially beneficial way for maintaining a healthy colon function (Asp et al., 1997; Kleessen et al., 1997; Bird et al., 2000; Haralampu, 2000; Topping and Clifton, 2001; Brouns et al., 2002) . The increasing knowledge of starch digestion in humans has allowed a new classification of types of RS that has now been commonly accepted (Englyst et al., 1992 Champ et al., 2003) . Three classes of RS are usually described in literature but recently a fourth class also has been described: RS 1 : physically inaccessible starch. It is found in partly milled grains and seeds. Legumes such as beans or lentils are important sources of RS type 1. RS 2 : RS granules. Raw B-type starches, such as raw potato and banana starch, are known to be very resistant to enzymatic hydrolysis when uncooked. Raw type II RSs are classified in three main types, for example: (1) most native cereal starches and cassava starch; (2) raw potato and banana starches (Englyst and Cummings, 1986; Faisant et al., 1995a) ; and (3) most raw legume starches. Most cooking procedures are able to gelatinize raw starches allowing the disappearance of RS 2 in the food. Accordingly, banana, which is mostly consumed raw, is the main source of RS 2 in the human diet.
The content of the latter depends on the degree of ripening. RS 3 : retrograded starch. This is present in most starchy foods, which have been cooked, then cooled and stored for several hours, up to several months. Retrogradation is a recrystallization of starch polymer chains, which occurs after the gelatinization. Cooked and cooled potatoes have been shown to contain RS 3 in significant amounts (Englyst and Cummings, 1987; Kingman and Englyst, 1994) . RS 4 : chemically modified starch. It has recently been described, and includes starch ethers and esters as well as cross-bonded starches that are resistant to small intestinal digestion (Asp et al., 1996; Baghurst et al., 1996) . RS 1 , RS 2 and/or RS 3 can coexist in the same food. A meal of beans, for example, contains both RS 1 and RS 3 (Noah et al., 1998) , whereas RS 1 and RS 2 are present in bananas (Faisant et al., 1995a, b) . RS is present in a wide variety of starchy foods and may constitute up to 15% of the dry matter in a food product. Several studies suggest that its presence in food might be beneficial to health (Asp et al., 1996) . RS is by definition not absorbed in the small intestine (Asp, 1992) and does not contribute to postprandial hyperglycaemia . When added to the meals, RS may be beneficial for patients with hypertriglyridaemia (Faisant et al., 1994) . Some animal studies indicate a serum cholesterol lowering effect, but such effects in humans have not been demonstrated (Heijnen et al., 1996) . A number of studies of the effect of RS on bowel habit and intestinal bulk have been reported, but findings are somewhat inconsistent (Baghurst et al., 1996) . RS type 1, 2 and 3 are known to be completely fermentable, resulting in relatively high quantities of short-chain-fatty acids. RS is supposed to contribute to colonic health through effects on gut flora, intestinal pH reduction, secondary bile acids reduction, elevated butyrate production and reductions in putrefactive protein fermentation as well as in luminal ammonia concentrations. Although these effects are generally supposed to beneficially impact on health, not all studies show a positive outcome on measured clinical endpoints (Edwards et al., 1995; Hylla et al., 1998; Topping and Clifton, 2001 ). Type 4 RS may differ in fermentation behaviour depending on its modified molecular structure. Recently, a number of review publications have highlighted the physiological properties as well as the effects of RSs on intestinal digestion, physiology, flora and fermentation (Cummings and Englyst, 1991; Cummings et al., 1996; Topping and Bird, 1999; Bird et al., 2000; Topping and Clifton, 2001; Champ 2003) . The aim of the study presented here was to define the gastrointestinal (GI) tolerance to the ingestion of retrograded resistant maltodextrins (RRMs) obtained after partial hydrolysis of starch and subsequent retrogradation. The latter results in the formation of indigestible crystallites that have a molecular similarity to type 3 RS but with a smaller degree of polymerization as well as a lower molecular weight (European Patent Office, EP 0 846 704).
In this paper, we present the results concerning: (1) The GI responses of healthy young adults following consumption of foods fortified with 0-60 g RRM (2) Effect of daily ingestion of RRM in gradually increasing quantities for a period of 21 days, finally exceeding the maximum non-effective dose (MNED) as determined after acute ingestion.
Methods
Subjects Forty-one healthy volunteers, aged between 18 and 24 years, were randomly recruited from the student population of the University of Salford. The purpose and nature of the proposed studies were explained to volunteers, who provided written consent, and were free to leave the studies at any time and for any reason, without further explanation. The study was approved by the Medical Ethical Committee of the University of Salford, Department of Occupational Health and Hygiene Service. Potential recruits were screened according to the methods of Lee and Storey (1999) . A total of 20 male subjects and 21 female subjects participated in both studies with body mass indices (mean þ s.d.) of 23.99 þ 2.73 and 23.01 þ 4.87 kg/m 2 for males and females, respectively. All subjects completed part 1 of the study and 39 subjects completed study part 2. One male subject did not wish to participate in the second part of the study. One other male subject failed to consume Gastrointestinal responses to retrograded resistant maltodextrins D Storey et al test products during days 15-21 of study part 2 because he disliked the taste and texture of food products supplied for consumption. No subject left either part of the study because of perceived GI symptoms following consumption of the RRM containing products. Subjects received remuneration for travel expenses and for any inconvenience related to participating in the study.
Test materials
The digestion-resistant carbohydrate source used in this study is ActistarRM. It is equivalent to type III RS that is formed in many staple starchy foods in which retrogradation happens as a result of traditional culinary practices, as acknowledged in 2003 by AFSSA, the French food safety agency. 'It is obtained from a partially hydrolysed starch (tapioca or potato) by enzymatic de-branching with isoamylase, followed by subsequent retrogradation (10). It consists of linear a-D-glucans of which more than 50% have a polymerization degree between 10 and 35 in the resistant fraction. Studies in ileostomy patients (Langkilde et al., 2002) have shown that the non-digestible fraction of the product amounts to 59%, the remainder being digestible carbohydrate'. The indigestible RRM fraction is quantified appropriately by the 2002.02 AOAC method for measuring RS (Champ et al., 2003) . In both parts of the study a powdered chocolate drink and a dried vegetable soup, containing either digestible starch (DS) or RRM containing product, were provided in bags, in addition to a menu of cereal bars and breakfast muesli. Subjects were instructed to prepare the chocolate drink and vegetable soup by the addition of approximately 200 ml freshly boiled water and, as with other drinks, to consume it after it had been allowed to cool adequately. Daily menus were presented in a plain package and identified by a code number, subject number and test day. The identity of products was not revealed to the investigators until completion of both study parts 1 and 2. All subjects were instructed to continue consumption of their normal diet and make the supplied food part of it.
In study part 1, each daily menu contained four cereal snack bars (25 g each), two powdered chocolate drinks (35 g each), two dried vegetable soups (45 g each) and one breakfast muesli (50 g). Cereal snack bars contained 5 g total starch and all other foods 20 g total starch each. Foods formulated with RRM contained at least 50% RRM. DS and RRM containing foods were mixed in daily menus to provide an additional total of 0, 10, 20, 30, 40, 50 and 60 g RS, as presented in Table 1 .
In study part 2, cereal snack bars contained 1.8 g RS, chocolate drink 10.3 g RRM, breakfast muesli 10 g RRM and vegetable soup 11.1 g RRM. The composition of the daily menus and total dose of RRM, provided on study days 1-21, for subjects whose MNED was either 40, 50 or 60 g RRM (as defined in study 1) is shown in Table 2 .
Study design and restrictions
Study part 1 was executed according to a double blind, placebo controlled crossover design. Subjects were tested with each product in randomized order determined by a Latin square design applied to each leg of the crossover study. Subjects consumed 0, 10, 20, 30, 40, 50 or 60 g RRM by eating various combinations of products (Table 1) . Test days were separated by washout periods of 1 week.
Study part 2 was conducted 6 weeks after completion of part 1 as a longitudinal study in which RRM consumption was increased in incremental doses from 0 g at day 1 up to each subject's MNED level (highest non-symptom dose level as determined in study part 1) to be reached on day 14. RRM intake was then increased further in small incremental doses from day 15 to 21 in such a way that the final intake of RRM at day 21 is at least 10 g above the individual MNED level (Table 2) .
In both parts of the study dietary restrictions were enforced according to Lee and Storey (1999) . Subjects were instructed to maintain their normal dietary habits and to consume the muesli as breakfast in place of other breakfast cereals and to incorporate consumption of soup and chocolate drinks into their normal mid-day and evening meals. They were allowed to consume the cereal snack bars as mid-morning or mid-afternoon snacks but were requested not to consume products at extreme times of day and not to eat the test products as a total replacement for their normal meals. Each subject was individually debriefed 24 h after DS  DS  DS  DS  DS  120  0  120  Menu 2  RS3  DS  DS  DS  DS  DS  110  10  120  Menu 3  RS3  DS  RS3  DS  DS  DS  100  20  120  Menu 4  RS3  RS3  RS3  DS  DS  DS  90  30  120  Menu 5  RS3  RS3  RS3  DS  DS  RS3  80  40  120  Menu 6  RS3  RS3  RS3  RS3  DS  RS3  70  50  120  Menu 7  RS3  RS3  RS3  RS3  RS3  RS3  60  60  120 Gastrointestinal responses to retrograded resistant maltodextrins D Storey et al consumption of each product to determine adherence to dietary restrictions and consumption regime and to assess GI responses.
Gastrointestinal symptoms
In both parts of the study, subjects were given printed sheets on which to record the incidence and magnitude of GI responses and details of their bowel movements for the 24 h following consumption of the test products. Responses to be scored were nausea, borborygmi (audible bowel sounds), colic, bloating and flatulence. Each response was ranked on a hedonic scale where 0 indicated 'normal' function, 1 indicated 'slightly more symptom than usual', 2 indicated 'noticeably more symptom than usual' and 3 indicated 'considerably more symptom than usual'. Subjects recorded the number of bowel movements to pass faeces of normal, hard or watery consistency where watery faeces were defined as those of an abnormally watery consistency. Information regarding faecal volume was not gathered.
Statistics
In study part 1, symptom responses were regarded as categorical (yes/no), and considered to be non-parametric. Products were compared by 2 Â 2 contingency table analysis (w 2 ) according to the methods of McNemar (1947) to test for differences in symptomatology following consumption of products. The binomial test was used when the expected frequency in each cell of the contingency table was less than 5. w 2 was used to test for differences in the occurrence of multiple symptoms following consumption of products. The frequency of bowel movements to pass normal, watery or hard faeces were tested for distribution and found to be normally distributed and were analysed by one-way ANOVA followed by Scheffe post hoc test in case of significant dose level effects. Dose response effects were analysed by linear regression of mean symptom scores following consumption of 0-60 g RRM products. In study 2, the frequency of bowel movements to pass normal, watery and hard faeces and mean symptom scores following consumption of RRM containing products over 21 days were analysed by linear regression. The number of subjects experiencing symptoms and mean symptom scores from days 14 to 21 of study 2 were analysed by the Kolmogorov-Smirnov goodness of fit test (Siegel, 1988) .
Results
Study part 1 Table 3 shows the number of subjects experiencing GI symptoms following consumption of foods containing 0-60 g RRM (equivalent to 0-120 g RRM containing starch product). There were no significant differences in the number of subjects experiencing any symptom following consumption of 0-60 g RRM in food products as determined by contingency table analysis (w 2 ). Compared to 0 g RRM consumption of 60 g RRM was not associated with a Gastrointestinal responses to retrograded resistant maltodextrins D Storey et al significant change in either bowel movement frequency or faecal consistency. A mean symptom score was derived for each symptom by summing responses for each symptom and dividing by number. Regression analysis of mean symptom scores for nausea, bloating, borborygmi, colic and flatulence and bowel movement frequencies revealed no significant dose-dependent effects following consumption of 0-60 g RRM in food products (Figure 1 ). There were no significant differences in the number of subjects experiencing multiple symptoms when graded as 'slightly', 'noticeably' or 'considerably' more than usual following consumption of foods containing 0-60 g RRM (Table 4) . The MNED was defined as the highest dose of RRM ingested that did not provoke considerably more than usual digestive symptoms (nausea, bloating, borborygmi, colic and flatulence) or more than one bowel movement to pass watery faeces or four or more bowel movements to pass faeces of any consistency. In total, three subjects had a MNED of 40 g RRM, eight subjects 50 g RRM and 30 subjects 60 g RRM. The results obtained from this part of the study were used to determine the dose of RRM to be given to subjects in part 2 of the study (Table 2) .
Study part 2
Study participants classified the majority of GI responses following consumption of increasing doses of RS, over a period of 21 days, as 'a little more than usual'. Analysis of mean bowel movement frequencies by linear regression analysis indicated a significant dose-dependent increase in total bowel movement frequency (P ¼ 0.023) and in bowel movement frequency to pass watery faeces (P ¼ 0.0157) during the 21 days of RRM consumption (Figure 2 ). Furthermore, prolonged consumption of increasing doses of RRM in food products was associated with a significant increase in the mean symptom score for flatulence but not for nausea, bloating, borborygmi or colic (Figure 3) . Analysis by the Kolmogorov-Smirnov goodness-of-fit test of the number of subjects experiencing symptoms and mean symptom scores (Figure 3 ) revealed no significant differences in symptom responses between days 14-21.
Discussion
Considering its potential application possibilities as a food ingredient in low glycaemic and functional foods, surprisingly little is known about the GI tolerance of RS. RS consumption has historically declined over a period of 40 years from initially 7-9 g to 3-7 g/day in recent years (Brousseau et al, 1998) , most probably because of changed food habits related to a rapidly industrialized world and a reduced overall stock consumption. Currently calculated intakes range from about 4 to 8.5 g/day in European countries (Tomlin and Read, 1990; Brighenti et al., 1998; Wisker, 2000) , which is comparable to quantities consumed in Australia (Baghurst et al., 1996) . However, it has been suggested that in some individuals, consuming high amounts of starch containing foods, daily intake of RS may be substantially higher (Champ et al., 2003) . In some clinical studies amounts up to 45 g/day have been ingested (van Munster et al., 1994; Phillips et al., 1995; Heijnen et al., 1997) , but no data were mentioned on digestive tolerance. Moreover, controlled studies on digestive tolerance to RS have not been done so far.
In part 1 of the present study, subjects consumed up to 60 g RRM, in addition to any other dietary fibre and RS b   None  37  31  36  32  36  34  30  1  3  8  3  6  5  5  6  2  1  2  1  1  0  2  2  3 þ  0  0  1  2  0  0  3  Total  4  10  5  9  5  7  11 a 0, no more symptom than usual; 1, slightly more symptom than usual; 2, noticeably more symptom than usual; 3, considerably more symptom than usual. b Number of bowel movements to pass watery faeces.
Watery Faeces
intake, with their normal diet. It was observed that consumption of up to 60 g RRM in food products was tolerated very well with no significant increase in the number of subjects experiencing those GI symptoms or multiple symptoms commonly associated with ingestion of high doses of indigestible carbohydrates (Table 3) . These results are consistent with those of van Munster et al. (1994) , who reported that continued consumption of 28 g type 2 RS was well tolerated by healthy volunteers. The MNED was defined as 60 g RRM in 73% of subjects indicating that a maximum dose of 60 g RRM could be tolerated without the occurrence of considerably more GI symptoms or watery faeces. Studies in which fructo-oligosaccharides (FOS), which have similar product applications were ingested, the MNED has been estimated as approximately 40-50 g for males and females, respectively, based upon the occurrence of diarrhoea (Hata et al., 1991) . FOS have also been shown to provoke flatulence at 30 g and borborygmi, bloating and abdominal cramps at 40 g (Briet et al., 1995) . Results also compare favourably with investigations where consumption of partly digestible carbohydrates such as 20 g D-tagatose, 30 g and 40 g isomalt, maltitol and lactitol led to significant increases in GI symptoms in young adults (Koutsou et al., 1996; Lee and Storey, 1999) . Furthermore, consumption of up to 60 g RRM did not result in significant dose-dependent effects in contrast to Gastrointestinal responses to retrograded resistant maltodextrins D Storey et al significant dose-dependent effects observed in young adults following consumption of polyol sugars (Koutsou et al., 1996) and adults consuming FOS (Briet et al., 1995) . In this respect it needs to be noted that RRM has a more polymerized structure and higher molecular weight compared to low molecular weight, osmotically active Figure 3 21 days of RRM consumption in food products was associated with a significant increase in the mean symptom score for flatulence but not for nausea, bloating, borborygmi or colic.
carbohydrates such as polyols. This and other factors, such as the reportedly relatively slow fermentation in the colon resulting in low gas formation (Olesen et al., 1994; Achour et al., 1997) may explain why RS is so much tolerated better than other types of carbohydrate that are partly digestible or indigestible.
Only few subjects passed watery faeces on more than one occasion, following consumption of products containing high amounts of RRM. Overall only three subjects passed watery faeces more than three times following consumption of 460 g RRM. These results suggest that at very high intakes, RRM may have a laxative effect in some individuals, as also previously reported by Phillips et al. (1995) and Cummings et al. (1996) . In the present study, faecal volume was not determined. However, the results of the present study indicate an increased moisture content of the faeces with increasing RRM intake, which suggests that RRM moderately moisturizes faecal matter and affects bulk as has been shown in other studies (Phillips et al., 1995; Cummings et al., 1996) . The latter has been identified as potentially beneficial for colonic mucosal health and the prevention of large bowel intestinal disorders, notably by reducing pH, increasing luminal contents of short-chainfatty acids, reducing luminal ammonia, secondary bile acids and faecal water toxicity (Tomlin and Read, 1990; Cummings et al., 1992; Van Munster and Nagengast, 1993; Birkett et al., 1997; Hylla et al., 1998; Topping and Clifton, 2001 ).
Study part 2 was designed to investigate if subjects could tolerate at least 10 g RRM over their MNED (during study days 14-21) following initial ingestion of increasing doses of RRM during a 14-days lasting period. It was also of interest to determine whether changes in GI tolerance occur following ingestion of increasing doses of RRM over 21 days. GI tolerance modification, following repeated ingestion of partially or indigestible carbohydrates, is supposed to occur because of adaptations in the enzymatic activity of the intestinal microflora. Colonic bacterial glucosidases are known to be substrate inducible (Macfarlane et al., 1988) and increased fermentation in the colon may decrease or even suppress diarrhoea by removing the osmotic effect of malabsorbed carbohydrates (Rambaud and Flourié, 1994) as well as stimulation of colonic sodium and water transport by short-chain-fatty acids resulting from the fermentation process. Reduction in diarrhoea following chronic ingestion of lactulose in lactose maldigesters has also been observed (Flourié et al., 1993) and a significant reduction in breath hydrogen excretion, diarrhoea and flatus has been reported following consumption of lactose after adaptive feeding periods (Johnson et al., 1993; Hertzler and Savaiano, 1996) .
In this study, significant dose-dependent increases in the symptom score for flatus, total bowel movement frequency and bowel movement frequency from day 1 to 21 of the study were observed, but no significant decrease or increase in symptoms from day 14 to 21 was observed. These results indicate that no adaptation occurred. In a similarly designed study, chronic ingestion of FOS did not improve GI tolerance or reduce breath hydrogen excretion in healthy subjects (Briet et al., 1995) . Although adaptive metabolic changes in colonic flora have been observed in response to ingestion of different types of RS (LeBlay et al., 1999; Silvi et al., 1999) , it is possible that ingestion of RRM for only 21 days was not sufficient to induce measurable adaptation effects.
